PKIDB: A curated database of protein kinase inhibitors in clinical trials


Latest updates : 2018-01-11
Structures and data are compiled by SB&C Team from the Chembl Drugstore and clinicaltrials.gov
Please note that we provide inhibitors with known International Nonproprietary Names (INN). For more information see the USAN nomenclature.

Additional molecular descriptors were calculated with RDKit version 2017.09.2.

The 10 following inhibitors have been excluded from table because they have no structure
Alflutinib, Cafusertib, Chiauranib, Cipatinib, Epitinib, Kanitinib, Metatinib, Puquitinib, Sulfatinib, Theliatinib

All fields of the table are sortable by clicking on the column header

Name Phase Applicants Links LigID pdbID Type RoF MW LogP TPSA HBA HBD NRB Indications Targets Canonical_Smiles_Inchi_key First_Approval SC_Patent Chirality Synonyms
Oclacitinib
0 Pfizer ChemSpider
ChEMBL
FDA SRS
NaN NaN nan 0 337.2 1.5 91 5 2 5 nan JAK1
JAK2
JAK3
Smiles=CNS(=O)(=O)C[C@H]1CC[C@@H](CC1)N(c2ncnc3c2cc[nH]3)C
Inchi Key=HJWLJNBZVZDLAQ-HAQNSBGRSA-N
nan nan Single Stereoisomer PF-03394197-11
OCLACITINIB
OCLACITINIB MALEATE
JAKI
PF-03394197
Toceranib
0 Pfizer ChemSpider
ChEMBL
PubChem
ZINC
FDA SRS
BindingDB
NaN NaN nan 0 396.2 3.1 77.2 3 3 5 nan KIT Smiles=Cc1c([nH]c(c1C(=O)NCCN2CCCC2)C)/C=C\3/c4cc(ccc4NC3=O)F
Inchi Key=SRSGVKWWVXWSJT-ATVHPVEESA-N
nan nan Achiral Molecule TOCERANIB PHOSPHATE
PHA-291639
TOCERANIB
PHA-291639E
Selatinib
1 Qilu Pharmaceutical ChemSpider
ChEMBL
PubChem
NaN NaN nan 2 564.1 6.5 89.3 7 2 11 nan EGFR
ERBB2
Smiles=CS(=O)CCNCc1ccc(o1)c2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5cccc(c5)F
Inchi Key=OAMVGUFHZPRXOM-UHFFFAOYSA-N
nan nan nan
Balamapimod
1 Wyeth ChemSpider
ChEMBL
PubChem
ZINC
FDA SRS
NaN NaN nan 2 573.2 6.5 82.2 9 1 7 nan RAF1
MAP2K1
MAP2K2
Smiles=Cn1ccnc1Sc2ccc(cc2Cl)Nc3c4cc(c(cc4ncc3C#N)N5CCC(CC5)N6CCCC6)OC
Inchi Key=CVAKNHIXTWLGJO-UHFFFAOYSA-N
nan nan Achiral Molecule MKI-833
BALAMAPIMOD
Pexmetinib
1 Array BioPharma ChemSpider
PubChem
ZINC
FDA SRS
NaN NaN nan 2 556.3 6.1 106.2 7 3 8 nan MAPK14
TEK
Smiles=Cc1ccc(cc1)n2c(cc(n2)C(C)(C)C)NC(=O)NCc3cc(ccc3Oc4ccc5c(c4)cnn5CCO)F
Inchi Key=LNMRSSIMGCDUTP-UHFFFAOYSA-N
nan nan Single Stereoisomer
Altiratinib
1 Deciphera Pharmaceuticals ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 1 510.2 5 109.4 5 3 8 nan MET
TEK
KDR
NTRK1
Smiles=c1cc(ccc1NC(=O)C2(CC2)C(=O)Nc3cc(c(cc3F)Oc4ccnc(c4)NC(=O)C5CC5)F)F
Inchi Key=GNNDEPIMDAZHRQ-UHFFFAOYSA-N
nan nan Achiral Molecule DCC-2701
ALTIRATINIB
DP-5164
Cenisertib
1 Rigel Pharmaceuticals;EMD Serono ChemSpider
ChEMBL
PubChem
ZINC
FDA SRS
BindingDB
NaN NaN nan 0 451.2 2.5 99.4 7 3 6 nan AURKA
AURKB
AURKC
Smiles=Cc1cc(ccc1N2CCN(CC2)C)Nc3ncc(c(n3)N[C@@H]4[C@@H]5C[C@H]([C@@H]4C(=O)N)C=C5)F
Inchi Key=KSOVGRCOLZZTPF-QMKUDKLTSA-N
nan nan Racemic Mixture AS-703569
R-763
Panulisib
1 Piramal Enterprises ChemSpider
PubChem
ZINC
NaN NaN nan 1 527.2 4.8 134.5 9 1 3 nan PIK3CA
MTOR
Smiles=CC(C)(C#N)c1ccc(cn1)n2c3c4cc(ccc4ncc3n(c2=NC#N)C)c5cc(c(nc5)N)C(F)(F)F
Inchi Key=VJLRLTSXTLICIR-UHFFFAOYSA-N
nan nan Single Stereoisomer
Allitinib
1 Allist Pharmaceuticals ChemSpider
ChEMBL
PubChem
ZINC
NaN NaN nan 1 448.1 5.9 76.1 5 2 7 nan ERBB2
EGFR
Smiles=C=CC(=O)Nc1ccc2c(c1)c(ncn2)Nc3ccc(c(c3)Cl)OCc4cccc(c4)F
Inchi Key=MVZGYPSXNDCANY-UHFFFAOYSA-N
nan nan Single Stereoisomer ALL-3
AST-1306
Omipalisib
1 GlaxosmithKline ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
ZIG 3l08 1 1 505.1 4.8 107 7 1 6 nan PIK3CA
MTOR
Smiles=COc1c(cc(cn1)c2ccc3c(c2)c(ccn3)c4ccnnc4)NS(=O)(=O)c5ccc(cc5F)F
Inchi Key=CGBJSGAELGCMKE-UHFFFAOYSA-N
nan nan Achiral Molecule GSK2126458
GSK-2126458
OMIPALISIB
Mubritinib
1 Takeda ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 1 468.2 6.1 66 6 0 10 nan EGFR
ERBB2
Smiles=c1cc(ccc1CCCCn2ccnn2)OCc3coc(n3)/C=C/c4ccc(cc4)C(F)(F)F
Inchi Key=ZTFBIUXIQYRUNT-MDWZMJQESA-N
nan nan Achiral Molecule MUBRITINIB
TAK-165
Henatinib
1 Jiangsu Hengrui Medicine ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS
BindingDB
NaN NaN nan 0 468.2 2 97.9 5 3 5 nan KDR Smiles=Cc1c([nH]c2c1C(=O)N(CCC2)C[C@@H](CN3CCOCC3)O)/C=C\4/c5cc(ccc5NC4=O)F
Inchi Key=MCTXSDCWFQAGFS-UEXNTNOUSA-N
nan nan Single Stereoisomer
Recilisib
1 Onconova Therapeutics ChemSpider
ChEMBL
PubChem
ZINC
FDA SRS
NaN NaN nan 0 336 3.6 71.4 3 1 5 nan nan Smiles=c1cc(ccc1CS(=O)(=O)/C=C/c2ccc(cc2)C(=O)O)Cl
Inchi Key=KBEKQQJUNVQLDZ-MDZDMXLPSA-N
nan nan Achiral Molecule ON 01210
RECILISIB
ON 01210.Na
RECILISIB SODIUM
ON-01210
ON 01210. NA
Tafetinib
1 Nanjing Yoko Biomedical ChemSpider
ChEMBL
PubChem
ZINC
FDA SRS
BindingDB
NaN NaN nan 0 424.2 3.7 77.2 3 3 6 nan KDR
FLT4
FLT1
Smiles=CCN(CC)CCNC(=O)c1c([nH]c\2c1CCC/C2=C/3\c4cc(ccc4NC3=O)F)C
Inchi Key=KGSRYTUWXUESJK-FXBPSFAMSA-N
nan nan nan
Pexidartinib
1 Daiichi Sankyo ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
P31 4r7h 2 1 417.1 5.2 66.5 4 2 5 nan FLT3
KIT
CSF1R
Smiles=c1cc(ncc1Cc2c[nH]c3c2cc(cn3)Cl)NCc4ccc(nc4)C(F)(F)F
Inchi Key=JGWRKYUXBBNENE-UHFFFAOYSA-N
nan nan nan
Amcasertib
1.5 Boston Biomedical ChemSpider
ChEMBL
PubChem
ZINC
FDA SRS
NaN NaN nan 2 539.2 6 90.1 5 3 9 nan PDGFRA Smiles=CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)c4csc(n4)c5ccccc5)C
Inchi Key=QDWKGEFGLQMDAM-ULJHMMPZSA-N
nan nan Achiral Molecule BBI503
AMCASERTIB
Telatinib
2 Bayer ChemSpider
ChEMBL
PubChem
ZINC
FDA SRS
BindingDB
NaN NaN nan 0 409.1 4 102.2 7 2 6 nan KDR
FLT4
Smiles=CNC(=O)c1cc(ccn1)COc2c3c(cco3)c(nn2)Nc4ccc(cc4)Cl
Inchi Key=QFCXANHHBCGMAS-UHFFFAOYSA-N
nan nan Achiral Molecule BAY-579352
Telatinib
BAY-57-9352
Pelitinib
2 Wyeth ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
93J 5vcw 1 1 467.2 5.1 90.3 6 2 8 nan EGFR
ERBB2
Smiles=CCOc1cc2c(cc1NC(=O)/C=C/CN(C)C)c(c(cn2)C#N)Nc3ccc(c(c3)Cl)F
Inchi Key=WVUNYSQLFKLYNI-AATRIKPKSA-N
nan nan Achiral Molecule EKB-569
PELITINIB
WAY-EKB-569
Silmitasertib
2 Senhwa Biosciences ChemSpider
ChEMBL
PubChem
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
3NG 3nga 3pe1 5o11 1 0 349.1 4.9 75.1 4 2 3 nan CSNK2A1
CSNK2A2
Smiles=c1cc(cc(c1)Cl)Nc2c3ccncc3c4ccc(cc4n2)C(=O)O
Inchi Key=MUOKSQABCJCOPU-UHFFFAOYSA-N
nan nan Achiral Molecule CX-4945
Silmitasertib
Sonolisib
2 Cascadian Therapeutics ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 1 525.2 3.1 119.4 9 1 8 nan PIK3CA
PIK3CB
PIK3CG
Smiles=CC(=O)O[C@@H]1C[C@]2([C@@H](CCC2=O)C3=C1[C@]4([C@H](OC(=O)/C(=C/N(CC=C)CC=C)/C4=C(C3=O)O)COC)C)C
Inchi Key=QIUASFSNWYMDFS-NILGECQDSA-N
nan nan Single Stereoisomer Sonolisib
PX-866
Tamatinib
2 Rigel Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
585 3fqs 3piy 1 0 470.2 3.6 128.8 10 3 7 nan SYK Smiles=CC1(C(=O)Nc2c(ccc(n2)Nc3c(cnc(n3)Nc4cc(c(c(c4)OC)OC)OC)F)O1)C
Inchi Key=NHHQJBCNYHBUSI-UHFFFAOYSA-N
nan nan Achiral Molecule R-406
Tozasertib
2 Merck ChemSpider
ChEMBL
PubChem
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
VX6 2f4j 2xyn 3amb 3e5a 4af3 4b8m 4jbq 4zog 1 0 464.2 3.5 102.1 8 3 7 nan AURKA
AURKB
AURKC
Smiles=Cc1cc(n[nH]1)Nc2cc(nc(n2)Sc3ccc(cc3)NC(=O)C4CC4)N5CCN(CC5)C
Inchi Key=GCIKSSRWRFVXBI-UHFFFAOYSA-N
nan nan Achiral Molecule MK-045
VX-68
TOZASERTIB
MK-0457
TOZASERTIB LACTATE
VX-680
Pamapimod
2 Hoffmann-La Roche ChemSpider
ChEMBL
PubChem
RCSB
PDBe
ZINC
FDA SRS
BindingDB
FLW 3flw 1 0 406.1 1.9 109.5 8 3 8 nan MAPK14
MAPK11
Smiles=Cn1c2c(cc(c1=O)Oc3ccc(cc3F)F)cnc(n2)NC(CCO)CCO
Inchi Key=JYYLVUFNAHSSFE-UHFFFAOYSA-N
nan nan Achiral Molecule PAMAPIMOD
JTT-705
R1503
RO 4402257
R-1503
Ro-4402257
Infigratinib
2 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
07J 3tt0 1 2 559.2 5.4 95.1 8 2 8 nan FGFR1
FGFR2
FGFR3
Smiles=CCN1CCN(CC1)c2ccc(cc2)Nc3cc(ncn3)N(C)C(=O)Nc4c(c(cc(c4Cl)OC)OC)Cl
Inchi Key=QADPYRIHXKWUSV-UHFFFAOYSA-N
nan nan Achiral Molecule BGJ-398
NVP-BGJ398
Afuresertib
2 GlaxoSmithKline ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 426 3.9 72.9 5 2 6 nan AKT1
AKT2
AKT3
Smiles=Cn1c(c(cn1)Cl)c2cc(sc2Cl)C(=O)N[C@@H](Cc3cccc(c3)F)CN
Inchi Key=AFJRDFWMXUECEW-LBPRGKRZSA-N
nan nan Single Stereoisomer GSK2110183C
GSK-2110183
GSK2110183B
AFURESERTIB
AFURESERTIB HYDROCHLORIDE
Bentamapimod
2 PregLem ChemSpider
ChEMBL
PubChem
NaN NaN nan 0 457.2 4.2 84.2 8 0 7 nan MAPK8
MAPK9
Smiles=N#CC(c1nc2ccccc2s1)c5nc(OCc3ccc(cc3)CN4CCOCC4)ncc5
Inchi Key=XCPPIJCBCWUBNT-UHFFFAOYSA-N
nan nan Racemic Mixture AS-602801
PGL-5001
Bentamapimod
Sapitinib
2 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN nan 0 473.2 3.8 88.6 7 2 7 nan EGFR
ERBB2
ERBB4
ERBB3
Smiles=CNC(=O)CN1CCC(CC1)Oc2cc3c(cc2OC)ncnc3Nc4cccc(c4F)Cl
Inchi Key=DFJSJLGUIXFDJP-UHFFFAOYSA-N
nan nan Achiral Molecule Sapitinib
AZD-8931
Decernotinib
2 Vertex Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
VJK 4yti 1 0 392.2 3.3 95.6 5 3 6 nan JAK3 Smiles=CC[C@](C)(C(=O)NCC(F)(F)F)Nc1ccnc(n1)c2c[nH]c3c2cccn3
Inchi Key=ASUGUQWIHMTFJL-QGZVFWFLSA-N
nan nan Single Stereoisomer ADELATINIB
VX-509
DECERNOTINIB
VRT-831509
Rabusertib
2 Eli Lilly ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 435.1 2.9 97.4 6 3 5 nan CHEK1 Smiles=Cc1cc(c(cc1Br)NC(=O)Nc2cnc(cn2)C)OC[C@@H]3CNCCO3
Inchi Key=SYYBDNPGDKKJDU-ZDUSSCGKSA-N
nan nan Single Stereoisomer LY-2603618
IC-83
RABUSERTIB
LY2603618
Olmutinib
2 Hanmi Pharmaceutical ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 1 486.2 5.1 82.6 8 2 7 For use in treatment of metastatic T790M mutation positive non-small cell lung cancer EGFR Smiles=CN1CCN(CC1)c2ccc(cc2)Nc3nc4ccsc4c(n3)Oc5cccc(c5)NC(=O)C=C
Inchi Key=FDMQDKQUTRLUBU-UHFFFAOYSA-N
nan nan Achiral Molecule OLMUTINIB
BI 1482694
HM61713
Dactolisib
2 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN nan 1 469.2 5.9 76.5 6 0 3 nan PIK3CA
PIK3CB
PIK3CG
PIK3CD
MTOR
Smiles=CC(C)(C#N)c1ccc(cc1)n2c3c4cc(ccc4ncc3n(c2=O)C)c5cc6ccccc6nc5
Inchi Key=JOGKUKXHTYWRGZ-UHFFFAOYSA-N
nan nan Achiral Molecule NVP-BEZ235-ANA
NVP-BEZ235-NX
BEZ-235
NVP-BEZ235
DACTOLISIB TOSYLATE
DACTOLISIB
Refametinib
2 Bayer ChemSpider
ChEMBL
PubChem
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
VRA 3e8n nan 1 572 3.5 107.9 6 4 9 nan MAP2K1 Smiles=COc1cc(c(c(c1NS(=O)(=O)C2(CC2)C[C@@H](CO)O)Nc3ccc(cc3F)I)F)F
Inchi Key=RDSACQWTXKSHJT-NSHDSACASA-N
nan nan Racemic Mixture BAY 86-9766
RDEA-119
REFAMETINIB;
RDEA119;
Lucitanib
2 Clovis Oncology ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
3ZC 4rwl 1 0 443.2 4.4 95.7 6 2 7 nan FLT1
KDR
FLT4
FGFR1
FGFR2
Smiles=CNC(=O)c1cccc2c1ccc(c2)Oc3ccnc4c3cc(c(c4)OCC5(CC5)N)OC
Inchi Key=CUDVHEFYRIWYQD-UHFFFAOYSA-N
nan nan Achiral Molecule S 80881
E-3810
LUCITANIB
CO-3810
AL-3810
Gedatolisib
2 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN nan 1 615.3 3 128.3 10 2 7 nan PIK3CA
PIK3CB
PIK3CG
PIK3CD
MTOR
Smiles=CN(C)C1CCN(CC1)C(=O)c2ccc(cc2)NC(=O)Nc3ccc(cc3)c4nc(nc(n4)N5CCOCC5)N6CCOCC6
Inchi Key=DWZAEMINVBZMHQ-UHFFFAOYSA-N
nan nan Achiral Molecule PF-05212384
GEDATOLISIB
PKI-587
Selonsertib
2 Gilead Sciences ChemSpider
PubChem
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 445.2 4.7 90.5 7 1 6 nan MAP3K5 Smiles=Cc1cc(c(cc1n2cc(nc2)C3CC3)C(=O)Nc4cccc(n4)c5nncn5C(C)C)F
Inchi Key=YIDDLAAKOYYGJG-UHFFFAOYSA-N
nan nan nan
Capmatinib
2 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 412.1 3.4 85.1 6 1 4 nan MET Smiles=CNC(=O)c1ccc(cc1F)c2cnc3ncc(n3n2)Cc4ccc5c(c4)cccn5
Inchi Key=LIOLIMKSCNQPLV-UHFFFAOYSA-N
nan nan Achiral Molecule INCB-28060
Capmatinib
INC-280
NVP-INC280
Anlotinib
2 Advenchen Laboratories ChemSpider
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 407.2 4.8 82.4 5 2 6 nan KDR
FLT4
Smiles=Cc1cc2c([nH]1)ccc(c2F)Oc3ccnc4c3cc(c(c4)OCC5(CC5)N)OC
Inchi Key=KSMZEXLVHXZPEF-UHFFFAOYSA-N
nan nan Single Stereoisomer ALTN
Amuvatinib
2 Supergen ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 447.1 3.3 75.9 7 1 3

Amuvatinib is a selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer cells.

KIT
MET
RET
FLT3
PDGFRB
Smiles=c1ccc2c(c1)c3c(o2)c(ncn3)N4CCN(CC4)C(=S)NCc5ccc6c(c5)OCO6
Inchi Key=FOFDIMHVKGYHRU-UHFFFAOYSA-N
nan nan Achiral Molecule MP-470.HCL
HPK56
AMUVATINIB HYDROCHLORIDE
HPK-56
MP470.HCL
MP-470
AMUVATINIB
MP470
Ilorasertib
2 Abbott Laboratories ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS
BindingDB
NaN NaN nan 1 488.1 5.2 118.1 7 4 6 nan AURKA
AURKB
AURKC
FLT1
PDGFRA
PDGFRB
Smiles=c1cc(cc(c1)F)NC(=O)Nc2ccc(cc2)c3csc4c3c(ncc4c5cnn(c5)CCO)N
Inchi Key=WPHKIQPVPYJNAX-UHFFFAOYSA-N
nan nan Achiral Molecule ILORASERTIB
ABT-348
A-968660
Golvatinib
2 Eisai ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
GV0 5ia5 2 1 633.3 4.8 119.1 7 3 8 nan MET
KDR
Smiles=CN1CCN(CC1)C2CCN(CC2)C(=O)Nc3cc(ccn3)Oc4ccc(c(c4)F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F
Inchi Key=UQRCJCNVNUFYDX-UHFFFAOYSA-N
nan nan Achiral Molecule GOLVATINIB
GOLVATINIB TARTRATE
ER-396901-08
E7050
E-7050
Glesatinib
2 Mirati Therapeutics ChemSpider
PubChem
ZINC
FDA SRS
NaN NaN nan 2 619.2 6.2 97.4 8 3 11 nan MET
TEK
FLT1
KDR
FLT4
MST1R
Smiles=COCCNCc1ccc(nc1)c2cc3c(s2)c(ccn3)Oc4ccc(cc4F)NC(=S)NC(=O)Cc5ccc(cc5)F
Inchi Key=YRCHYHRCBXNYNU-UHFFFAOYSA-N
nan nan nan
GCD265
Entospletinib
2 Gilead Sciences ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
CG9 4puz 1 0 411.2 3.9 83.4 7 2 4 nan SYK Smiles=c1cc(ccc1Nc2c3nccn3cc(n2)c4ccc5cn[nH]c5c4)N6CCOCC6
Inchi Key=XSMSNFMDVXXHGJ-UHFFFAOYSA-N
nan nan Achiral Molecule ENTOSPLETINIB
GS-9973
Entrectinib
2 Ignyta ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
YMX 5fto 5kvt 1 2 560.3 5 85.5 6 3 7 nan NTRK1
NTRK2
NTRK3
ROS1
ALK
Smiles=CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4c5cc(ccc5[nH]n4)Cc6cc(cc(c6)F)F
Inchi Key=HAYYBYPASCDWEQ-UHFFFAOYSA-N
nan nan Achiral Molecule NMS-E628
ENTRECTINIB
RXDX-101
Erdafitinib
2 Janssen ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
5SF 5ew8 1 0 446.2 4.2 77.3 8 1 9 nan FGFR1 Smiles=CC(C)NCCN(c1ccc2c(c1)nc(cn2)c3cnn(c3)C)c4cc(cc(c4)OC)OC
Inchi Key=OLAHOMJCDNXHFI-UHFFFAOYSA-N
nan nan nan JNJ-42756493
ERDAFITINIB
Larotrectinib
2 Array BioPharma ChemSpider
PubChem
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 428.2 2.9 86 6 2 3 nan NTRK1
NTRK2
NTRK3
Smiles=c1cc(c(cc1F)[C@H]2CCCN2c3ccn4c(n3)c(cn4)NC(=O)N5CC[C@@H](C5)O)F
Inchi Key=NYNZQNWKBKUAII-KBXCAEBGSA-N
nan nan nan ARRY 470
LOXO-101
LOXO 101
Evobrutinib
2 Merck ChemSpider
PubChem
ZINC
FDA SRS
NaN NaN nan 0 429.2 4.4 93.4 6 2 7 nan BTK Smiles=C=CC(=O)N1CCC(CC1)CNc2c(c(ncn2)N)c3ccc(cc3)Oc4ccccc4
Inchi Key=QUIWHXQETADMGN-UHFFFAOYSA-N
nan nan nan
EVOBRUTINIB
Ipatasertib
2 Hoffmann-La Roche ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
0RF 4ekl 1 0 457.2 3.1 81.6 6 2 6 nan AKT1
AKT2
AKT3
Smiles=C[C@@H]1C[C@H](c2c1c(ncn2)N3CCN(CC3)C(=O)[C@H](CNC(C)C)c4ccc(cc4)Cl)O
Inchi Key=GRZXWCHAXNAUHY-NSISKUIASA-N
nan nan Single Stereoisomer GDC-0068
RG-7440
RG7440
IPATASERTIB
Foretinib
2 GlaxoSmithKline ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
88Z 3lq8 5ia4 2 2 632.2 5.8 111.2 8 2 12 nan MET
KDR
Smiles=COc1cc2c(ccnc2cc1OCCCN3CCOCC3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F
Inchi Key=CXQHYVUVSFXTMY-UHFFFAOYSA-N
nan nan Achiral Molecule FORETINIB
EXEL-2880
GSK1363089G
GSK-089
XL-880
GSK-1363089
Galunisertib
2 Eli Lilly ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN nan 0 369.2 3.5 86.7 5 1 3 nan TGFBR1 Smiles=Cc1cccc(n1)c2c(c3n(n2)CCC3)c4ccnc5c4cc(cc5)C(=O)N
Inchi Key=IVRXNBXKWIJUQB-UHFFFAOYSA-N
nan nan Achiral Molecule GALUNISERTIB
LY-2157299
LY2157299
Defactinib
2 Verastem ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
7KD 5mah nan 1 510.1 2.4 142.1 9 3 8 nan PTK2
PTK2B
Smiles=CNC(=O)c1ccc(cc1)Nc2ncc(c(n2)NCc3c(nccn3)N(C)S(=O)(=O)C)C(F)(F)F
Inchi Key=FWLMVFUGMHIOAA-UHFFFAOYSA-N
nan nan Achiral Molecule DEFACTINIB HYDROCHLORIDE
VS-6063
DEFACTINIB
PF-04554878
Uprosertib
2 GlaxoSmithKline ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 428.1 3.6 86.1 5 2 6 nan AKT1
AKT2
AKT3
Smiles=Cn1c(c(cn1)Cl)c2cc(oc2Cl)C(=O)N[C@@H](Cc3ccc(c(c3)F)F)CN
Inchi Key=AXTAPYRUEKNRBA-JTQLQIEISA-N
nan nan Single Stereoisomer GSK-2141795
GSK2141795C
UPROSERTIB
Trilaciclib
2 G1 Therapeutics ChemSpider
PubChem
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 446.3 2.7 91.2 8 2 3 nan CDK4
CDK6
Smiles=CN1CCN(CC1)c2ccc(nc2)Nc3ncc4cc5n(c4n3)C6(CCCCC6)CNC5=O
Inchi Key=PDGKHKMBHVFCMG-UHFFFAOYSA-N
nan nan nan
Spebrutinib
2 Celgene ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 423.2 4.3 97.4 7 3 10 nan BTK Smiles=COCCOc1ccc(cc1)Nc2ncc(c(n2)Nc3cccc(c3)NC(=O)C=C)F
Inchi Key=KXBDTLQSDKGAEB-UHFFFAOYSA-N
nan nan Achiral Molecule SPEBRUTINIB BESYLATE
Spebrutinib
SPEBRUTINIB
AVL-292
CC-292
Apitolisib
2 Hoffmann-La Roche ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
980 3tl5 nan 1 498.2 0.9 133.8 11 2 5 nan PIK3CA
MTOR
Smiles=Cc1c(sc2c1nc(nc2N3CCOCC3)c4cnc(nc4)N)CN5CCN(CC5)C(=O)[C@H](C)O
Inchi Key=YOVVNQKCSKSHKT-HNNXBMFYSA-N
nan nan Single Stereoisomer GDC-0980
G-038390.1
APITOLISIB
G-038390
RG-7422
GDC-0980.1
RG7422
Tandutinib
2 Takeda ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS
BindingDB
NaN NaN nan 2 562.3 5 92.3 8 1 10 Investigated for use/treatment in leukemia (myeloid). FLT3
PDGFD
Smiles=CC(C)Oc1ccc(cc1)NC(=O)N2CCN(CC2)c3c4cc(c(cc4ncn3)OCCCN5CCCCC5)OC
Inchi Key=UXXQOJXBIDBUAC-UHFFFAOYSA-N
nan nan Achiral Molecule CT 53518
MLN-518
CT-53518
MLN-0518
TANDUTINIB
Tarloxotinib
2 Threshold Pharmaceuticals ChemSpider
PubChem
FDA SRS
NaN NaN nan 1 679 1.6 140.8 9 2 9 nan EGFR Smiles=Cn1cnc(c1C[N+](C)(C)C/C=C/C(=O)Nc2cc3c(cn2)ncnc3Nc4ccc(c(c4)Br)Cl)[N+](=O)[O-].[Br-]
Inchi Key=WAKIMVYUBWMMHJ-FXRZFVDSSA-N
nan nan nan
Tepotinib
2 Merck ChemSpider
ChEMBL
PubChem
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
300000000 4r1v 1 0 492.2 4 96.9 8 0 7 nan MET Smiles=CN1CCC(CC1)COc2cnc(nc2)c3cccc(c3)Cn4c(=O)ccc(n4)c5cccc(c5)C#N
Inchi Key=AHYMHWXQRWRBKT-UHFFFAOYSA-N
nan nan Achiral Molecule MSC-2156119J
Tepotinib
MSC-2156119
EMD-1214063
Tesevatinib
2 Kadmon Corporation ChemSpider
ChEMBL
DrugBank
ZINC
FDA SRS
NaN NaN nan 1 490.1 5.8 59.5 6 1 6 nan EGFR
ERBB2
KDR
FLT4
EPHB4
Smiles=CN1C[C@H]2C[C@H](C[C@H]2C1)COc3cc4c(cc3OC)c(ncn4)Nc5ccc(c(c5F)Cl)Cl
Inchi Key=HVXKQKFEHMGHSL-QKDCVEJESA-N
nan nan Racemic Mixture TESEVATINIB TOSYLATE
TESEVATINIB
KD-019
KD-020
XL-647
Pimasertib
2 Merck ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN nan 0 431 1.7 94.5 5 4 6 nan MAP2K1
MAP2K2
Smiles=c1cc(c(cc1I)F)Nc2cnccc2C(=O)NC[C@@H](CO)O
Inchi Key=VIUAUNHCRHHYNE-JTQLQIEISA-N
nan nan Single Stereoisomer MSC-1936369B
AS-703026
EMD 1036239
PIMASERTIB
Rebastinib
2 Deciphera Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
919 3qri 3qrj 5g6v 2 2 553.2 6 123.1 7 3 6 nan FLT3
TEK
KDR
LYN
BCR
ABL1
NTRK1
Smiles=CC(C)(C)c1cc(n(n1)c2ccc3c(c2)cccn3)NC(=O)Nc4ccc(cc4F)Oc5ccnc(c5)C(=O)NC
Inchi Key=WVXNSAVVKYZVOE-UHFFFAOYSA-N
nan nan Achiral Molecule REBASTINIB TOSYLATE
DP-1919
REBASTINIB
DCC-2036
Dilmapimod
2 GlaxoSmithKline ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 456.1 2.9 100.3 7 3 6

Dilmapimod has been used in trials studying the treatment and diagnostic of Nerve Trauma, Inflammation, Pain, Neuropathic, Arthritis, Rheumatoid, and Coronary Heart Disease, among others.

MAPK14
MAPK11
MAPK13
MAPK12
Smiles=Cc1cc(ccc1c2c3ccc(=O)n(c3nc(n2)NC(CO)CO)c4c(cccc4F)F)F
Inchi Key=ORVNHOYNEHYKJG-UHFFFAOYSA-N
nan nan Achiral Molecule SB-681323
GW-681323
DILMAPIMOD
SB-681323-T
DILMAPIMOD TOSYLATE
Gandotinib
2 Eli Lilly ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 469.2 4 83.4 7 2 6 nan JAK2 Smiles=Cc1cc(n[nH]1)Nc2cc(c3nc(c(n3n2)Cc4ccc(cc4F)Cl)C)CN5CCOCC5
Inchi Key=SQSZANZGUXWJEA-UHFFFAOYSA-N
nan nan Achiral Molecule LY-2784544
GANDOTINIB
Bafetinib
2 Innovive Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
406 2e2b 2 2 576.3 5.4 99.2 8 2 8 nan LYN
ABL1
Smiles=Cc1ccc(cc1Nc2nccc(n2)c3cncnc3)NC(=O)c4ccc(c(c4)C(F)(F)F)CN5CC[C@@H](C5)N(C)C
Inchi Key=ZGBAJMQHJDFTQJ-DEOSSOPVSA-N
nan nan Single Stereoisomer INNO-406
CNS-9
NS-187
BAFETINIB
Pictilisib
2 Hoffmann-La Roche ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
GD9 2wxp 2y3a 3dbs 1 1 513.2 2.1 107.6 9 1 5 nan PIK3CA
PIK3CB
PIK3CD
PIK3CG
Smiles=CS(=O)(=O)N1CCN(CC1)Cc2cc3c(s2)c(nc(n3)c4cccc5c4cn[nH]5)N6CCOCC6
Inchi Key=LHNIIDJUOCFXAP-UHFFFAOYSA-N
nan nan Achiral Molecule PICTILISIB
RG-7321
GDC-0941
Solcitinib
2 GlaxoSmithKline ChemSpider
ChEMBL
PubChem
ZINC
FDA SRS
BindingDB
NaN NaN nan 0 389.2 3.2 79.6 5 1 4 nan JAK1 Smiles=CC1(CN(C1)C(=O)c2ccc(cc2)c3cccc4n3nc(n4)NC(=O)C5CC5)C
Inchi Key=MPYACSQFXVMWNO-UHFFFAOYSA-N
nan nan Achiral Molecule GSK2586184A
GSK-2586184
GLPG-0778
SOLCITINIB
G154578
GLPG0778
GLPG-0788
Talmapimod
2 Scios inc ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
469 3hub 3zsh 1 1 512.2 4 65.9 5 0 5 Investigated for use/treatment in pain (acute or chronic) and rheumatoid arthritis. MAPK14 Smiles=C[C@@H]1CN([C@H](CN1C(=O)c2cc3c(cc2Cl)n(cc3C(=O)C(=O)N(C)C)C)C)Cc4ccc(cc4)F
Inchi Key=ZMELOYOKMZBMRB-DLBZAZTESA-N
nan nan Single Stereoisomer SCIO-469
TALMAPIMOD
SCIO 469
Tanzisertib
2 Celgene ChemSpider
ChEMBL
DrugBank
RCSB
PDBe
ZINC
FDA SRS
BindingDB
KBI 3tti 1 0 448.2 3.7 97.1 8 3 5 nan MAPK8 Smiles=c1c(c(c(cc1F)F)Nc2n(c3nc(ncc3n2)N[C@H]4CC[C@@H](CC4)O)[C@@H]5COCC5)F
Inchi Key=IBGLGMOPHJQDJB-IHRRRGAJSA-N
nan nan Single Stereoisomer TANZISERTIB
JNK-930
CC-930
Tucatinib
2 Array BioPharma ChemSpider
PubChem
DrugBank
ZINC
FDA SRS
NaN NaN nan 1 480.2 5.1 110.9 10 2 5 nan ERBB2 Smiles=Cc1cc(ccc1Oc2ccn3c(c2)ncn3)Nc4c5cc(ccc5ncn4)NC6=NC(CO6)(C)C
Inchi Key=SDEAXTCZPQIFQM-UHFFFAOYSA-N
nan nan nan
Poziotinib
2 Hanmi Pharmaceutical ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 1 490.1 5.4 76.6 6 1 6 nan EGFR Smiles=COc1cc2c(cc1OC3CCN(CC3)C(=O)C=C)c(ncn2)Nc4ccc(c(c4F)Cl)Cl
Inchi Key=LPFWVDIFUFFKJU-UHFFFAOYSA-N
nan nan Achiral Molecule NOV-120101
Poziotinib
HM-781-36B
Seliciclib
2 Cyclacel pharmaceuticals ChemSpider
ChEMBL
PubChem
BindingDB
NaN NaN 1 0 354.2 3.2 87.9 7 3 8 nan CDK2
CDK7
CDK9
Smiles=CCC(CO)Nc1nc(c2c(n1)n(cn2)C(C)C)NCc3ccccc3
Inchi Key=BTIHMVBBUGXLCJ-UHFFFAOYSA-N
nan nan Single Stereoisomer
Doramapimod
2 Boehringer Ingelheim ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
B96 1kv2 3fzs 3npc 4jvg 4twn 5n66 2 2 527.3 6 80.7 6 2 7 nan MAPK14 Smiles=Cc1ccc(cc1)n2c(cc(n2)C(C)(C)C)NC(=O)Nc3ccc(c4c3cccc4)OCCN5CCOCC5
Inchi Key=MVCOAUNKQVWQHZ-UHFFFAOYSA-N
nan nan Achiral Molecule BIRB-796
DORAMAPIMOD
Roniciclib
2 Bayer ChemSpider
PubChem
DrugBank
ZINC
FDA SRS
NaN NaN nan 0 430.1 4 108.2 7 3 7 nan CDK1
CDK2
CDK4
CDK9
Smiles=C[C@H]([C@@H](C)Oc1c(cnc(n1)Nc2ccc(cc2)[S@](=N)(=O)C3CC3)C(F)(F)F)O
Inchi Key=UELYDGOOJPRWGF-SRQXXRKNSA-N
nan nan Single Stereoisomer
Pilaralisib
2 Sanofi ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS
NaN NaN nan 1 540.1 4.5 148.3 8 4 8 nan PIK3CA
PIK3CB
PIK3CD
PIK3CG
Smiles=CC(C)(C(=O)Nc1cccc(c1)S(=O)(=O)Nc2c(nc3ccccc3n2)Nc4cc(ccc4Cl)OC)N
Inchi Key=QINPEPAQOBZPOF-UHFFFAOYSA-N
nan nan Achiral Molecule SAR-245408
XL-147
PILARALISIB
SAR245408
Voruciclib
2 Piramal Enterprises ChemSpider
PubChem
ZINC
FDA SRS
NaN NaN nan 0 469.1 4.3 94.1 6 3 3 nan CDK4 Smiles=CN1CC[C@H]([C@@H]1CO)c2c(cc(c3c2oc(cc3=O)c4ccc(cc4Cl)C(F)(F)F)O)O
Inchi Key=MRPGRAKIAJJGMM-OCCSQVGLSA-N
nan nan Single Stereoisomer
Acumapimod
2 Mereo BioPharma ChemSpider
PubChem
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 385.2 2.8 113.8 6 2 5 nan MAPK14
MAPK11
MAPK13
MAPK12
Smiles=Cc1ccc(cc1n2c(c(cn2)C(=O)c3cccc(c3)C#N)N)C(=O)NC4CC4
Inchi Key=VGUSQKZDZHAAEE-UHFFFAOYSA-N
nan nan Single Stereoisomer
Riviciclib
2 Piramal Enterprises ChemSpider
PubChem
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 401.1 3.3 94.1 6 3 3 nan CDK1
CDK4
CDK9
Smiles=CN1CC[C@H]([C@@H]1CO)c2c(cc(c3c2oc(cc3=O)c4ccccc4Cl)O)O
Inchi Key=QLUYMIVVAYRECT-OCCSQVGLSA-N
nan nan Racemic Mixture
Cerdulatinib
2 Portola pharmaceuticals ChemSpider
PubChem
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 445.2 1.4 133.6 8 3 8 nan JAK1
SYK
Smiles=CCS(=O)(=O)N1CCN(CC1)c2ccc(cc2)Nc3ncc(c(n3)NC4CC4)C(=O)N
Inchi Key=BGLPECHZZQDNCD-UHFFFAOYSA-N
nan nan Single Stereoisomer
PRT-062070
Merestinib
2 Eli Lilly ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
ZINC
FDA SRS
L1X 4eev 2 2 552.2 5.7 106.8 7 2 6 nan MET Smiles=Cc1ccc(c(=O)n1c2ccc(cc2)F)C(=O)Nc3ccc(c(c3)F)Oc4cc5cnn(c5cc4c6c[nH]nc6)C
Inchi Key=QHADVLVFMKEIIP-UHFFFAOYSA-N
nan nan Achiral Molecule LY2801653
LY-2801653
MERESTINIB
Ulixertinib
2 BioMed Valley Discoveries ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 432.1 4.7 90 4 4 7 nan MAPK1
MAPK3
Smiles=CC(C)Nc1cc(c(cn1)Cl)c2cc([nH]c2)C(=O)N[C@H](CO)c3cccc(c3)Cl
Inchi Key=KSERXGMCDHOLSS-LJQANCHMSA-N
nan nan Single Stereoisomer
Voxtalisib
2 Sanofi ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS
NaN NaN nan 0 270.1 1.1 102.5 6 2 2 nan PIK3CA
MTOR
Smiles=CCn1c2c(cc(c1=O)c3ccn[nH]3)c(nc(n2)N)C
Inchi Key=RGHYDLZMTYDBDT-UHFFFAOYSA-N
nan nan Achiral Molecule SAR-245409
XL765
VOXTALISIB
XL-765
Milciclib
2 Nerviano Medical Sciences ChemSpider
ChEMBL
PubChem
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
P48 2wih 5vc6 5vd1 1 0 460.3 2.6 91.2 8 2 4 nan CDK1
NTRK1
Smiles=CC1(Cc2cnc(nc2-c3c1c(nn3C)C(=O)NC)Nc4ccc(cc4)N5CCN(CC5)C)C
Inchi Key=RXZMYLDMFYNEIM-UHFFFAOYSA-N
nan nan Achiral Molecule Milciclib
PHA-848125
Sitravatinib
2 Mirati Therapeutics ChemSpider
PubChem
ZINC
FDA SRS
NaN NaN nan 2 629.2 6.5 114.5 8 3 12 nan RET
DDR2
NTRK1
NTRK2
NTRK3
Smiles=COCCNCc1ccc(nc1)c2cc3c(s2)c(ccn3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F
Inchi Key=WLAVZAAODLTUSW-UHFFFAOYSA-N
nan nan nan GCD516

SITRAVATINIB
Vistusertib
2 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN nan 0 462.2 2.5 92.7 8 1 4 nan MTOR Smiles=C[C@H]1COCCN1c2c3ccc(nc3nc(n2)N4CCOC[C@@H]4C)c5cccc(c5)C(=O)NC
Inchi Key=JUSFANSTBFGBAF-IRXDYDNUSA-N
nan nan nan AZD-2014
Acalisib
2 Gilead Sciences ChemSpider
PubChem
ZINC
FDA SRS
NaN NaN nan 0 401.1 3.4 101.4 7 2 4 nan PIK3CA Smiles=C[C@@H](c1nc2ccc(cc2c(=O)n1c3ccccc3)F)Nc4c5c(nc[nH]5)ncn4
Inchi Key=DOCINCLJNAXZQF-LBPRGKRZSA-N
nan nan Single Stereoisomer
CAL-120
Ralimetinib
2 Eli Lilly ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 1 420.2 5.6 85.4 5 2 3 nan MAPK14
MAPK11
Smiles=CC(C)(C)Cn1c2c(ccc(n2)c3c(nc([nH]3)C(C)(C)C)c4ccc(cc4)F)nc1N
Inchi Key=XPPBBJCBDOEXDN-UHFFFAOYSA-N
nan nan Achiral Molecule LY2228820 DIMESYLATE
RALIMETINIB MESYLATE
LSN2322600
LY22288220
LY-2228820
RALIMETINIB
Prexasertib
2 Eli Lilly ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 365.2 2.2 134.8 8 3 8 nan CHEK1
CHEK2
Smiles=COc1cccc(c1c2cc(n[nH]2)Nc3cnc(cn3)C#N)OCCCN
Inchi Key=DOTGPNHGTYJDEP-UHFFFAOYSA-N
nan nan Achiral Molecule LY2606368
PREXASERTIB
Danusertib
2 Nerviano Medical Sciences ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
627 2j50 2v7a 4qo9 5i9z 1 0 474.2 2.6 93.8 6 2 6 nan AURKA
AURKB
AURKC
Smiles=CN1CCN(CC1)c2ccc(cc2)C(=O)Nc3c4c([nH]n3)CN(C4)C(=O)[C@@H](c5ccccc5)OC
Inchi Key=XKFTZKGMDDZMJI-HSZRJFAPSA-N
nan nan Single Stereoisomer danusertib
PHA-739358
Sapanisertib
2 Takeda ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 309.1 2.4 121.7 8 2 2 nan MTOR Smiles=CC(C)n1c2c(c(n1)c3ccc4c(c3)nc(o4)N)c(ncn2)N
Inchi Key=GYLDXIAOMVERTK-UHFFFAOYSA-N
nan nan nan MLN-0128
Varlitinib
2.5 Array Biopharma ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 1 466.1 5.2 93.5 9 2 6 Investigated for use/treatment in cancer/tumors (unspecified). EGFR
ERBB2
Smiles=C[C@@H]1COC(=N1)Nc2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5nccs5
Inchi Key=UWXSAYUXVSFDBQ-CYBMUJFWSA-N
nan nan Single Stereoisomer ARRY-334543
VARLITINIB TOSYLATE
VARLITINIB
ARRY-543
AR00334543
ASLAN-001
AR00334543 ARRY-334543 ARRY-543
Linifanib
3 Abbott Laboratories ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN nan 0 375.1 4.9 95.8 3 4 3 nan FLT3
CSF1R
KDR
Smiles=Cc1ccc(c(c1)NC(=O)Nc2ccc(cc2)c3cccc4c3c(n[nH]4)N)F
Inchi Key=MPVGZUGXCQEXTM-UHFFFAOYSA-N
nan nan Achiral Molecule AL-39324
RG-3635
ABT-869
LINIFANIB
Selumetinib
3 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
3EW 4u7z 3 0 456 3.5 88.4 6 3 6 nan MAP2K1
MAP2K2
Smiles=Cn1cnc2c1cc(c(c2F)Nc3ccc(cc3Cl)Br)C(=O)NOCCO
Inchi Key=CYOHGALHFOKKQC-UHFFFAOYSA-N
nan nan Achiral Molecule AZD6244
ARRY-142886
AZD6244 HYD-SULFATE
AZD-6244
ARRY-886
SELUMETINIB
AZD6244 HYDROGEN SULFATE
SELUMETINIB SULFATE
Semaxanib
3 Sugen ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
X2M 2x2m 1 0 238.1 3.1 44.9 1 2 1 Investigated for use/treatment in colorectal cancer and lung cancer. KDR Smiles=Cc1cc([nH]c1/C=C\2/c3ccccc3NC2=O)C
Inchi Key=WUWDLXZGHZSWQZ-WQLSENKSSA-N
nan nan Achiral Molecule SU-5416
SEMAXANIB
Semaxinib
SU5416
Masitinib
3 AB Science ChemSpider
ChEMBL
PubChem
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
G65 5mql nan 1 498.2 5.3 73.4 7 2 7 nan KIT
PDGFRA
PDGFRB
FGFR1
FGFR2
FGFR3
Smiles=Cc1ccc(cc1Nc2nc(cs2)c3cccnc3)NC(=O)c4ccc(cc4)CN5CCN(CC5)C
Inchi Key=WJEOLQLKVOPQFV-UHFFFAOYSA-N
nan nan Achiral Molecule MASITINIB
AB-1010
Lestaurtinib
3 Cephalon; Kyowa Hakko; Teva Pharmaceutical Industries ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN nan 0 439.2 3.5 88.7 6 3 1 nan FLT3 Smiles=C[C@@]12[C@](C[C@@H](O1)n3c4ccccc4c5c3c6n2c7ccccc7c6c8c5C(=O)NC8)(CO)O
Inchi Key=UIARLYUEJFELEN-LROUJFHJSA-N
nan nan Single Stereoisomer CEP-701
LESTAURTINIB
SPM-924
SP-924
KT-555
A-154475.0
KT5555
A-154475
SP924
Radotinib
3 Il-Yang Pharmaceutical ChemSpider
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 2 530.2 5.8 110.5 8 2 6

Radotinib is indicated for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib.

ABL1
PDGFRB
Smiles=Cc1ccc(cc1Nc2nccc(n2)c3cnccn3)C(=O)Nc4cc(cc(c4)n5cc(nc5)C)C(F)(F)F
Inchi Key=DUPWHXBITIZIKZ-UHFFFAOYSA-N
nan nan nan
SUPEC
IY5511HCL
Naquotinib
3 Astellas Pharma ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 1 562.3 2.3 120.2 9 2 9 nan EGFR Smiles=CCc1c(nc(c(n1)C(=O)N)Nc2ccc(cc2)N3CCC(CC3)N4CCN(CC4)C)O[C@@H]5CCN(C5)C(=O)C=C
Inchi Key=QKDCLUARMDUUKN-XMMPIXPASA-N
nan nan Single Stereoisomer ASP8273
NAQUOTINIB MESYLATE
NAQUOTINIB
ASP8273 mesilate
Motesanib
3 Amgen ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
706 3efl 2 0 373.2 4 78.9 5 3 5 nan FLT1
KDR
FLT4
PDGFRA
PDGFRB
KIT
RET
Smiles=CC1(CNc2c1ccc(c2)NC(=O)c3cccnc3NCc4ccncc4)C
Inchi Key=RAHBGWKEPAQNFF-UHFFFAOYSA-N
nan nan Achiral Molecule MOTESANIB
AMG 706
MOTESANIB DIPHOSPHATE
AMG-706
Momelotinib
3 Ym Biosciences Australia ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN nan 0 414.2 3 103.2 7 2 6 nan JAK1
JAK2
JAK3
Smiles=c1cc(ccc1c2ccnc(n2)Nc3ccc(cc3)N4CCOCC4)C(=O)NCC#N
Inchi Key=ZVHNDZWQTBEVRY-UHFFFAOYSA-N
nan nan Achiral Molecule MOMELOTINIB DIHYDROCHLORIDE
CYT-11387
CYT387
GS-0387
CYT-387
MOMELOTINIB
Taselisib
3 Hoffmann-La Roche ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
799 5t8f 1 0 460.2 3.2 118.7 9 1 5 nan PIK3CA
PIK3CD
PIK3CG
Smiles=Cc1nc(n(n1)C(C)C)c2cn3c(n2)-c4ccc(cc4OCC3)c5cnn(c5)C(C)(C)C(=O)N
Inchi Key=BEUQXVWXFDOSAQ-UHFFFAOYSA-N
nan nan Racemic Mixture GDC-0032
RG-7604
TASELISIB
Savolitinib
3 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
ZINC
FDA SRS
V0L 5lbw nan 0 345.1 1.9 91.6 9 0 3 nan MET Smiles=C[C@@H](c1ccc2nccn2c1)n3c4c(ncc(n4)c5cnn(c5)C)nn3
Inchi Key=XYDNMOZJKOGZLS-NSHDSACASA-N
nan nan Single Stereoisomer
Saracatinib
3 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
H8H 2h8h 4qmx 5vcx 5vd3 1 1 541.2 3.9 90.4 10 1 8 nan SRC
ABL1
Smiles=CN1CCN(CC1)CCOc2cc3c(c(c2)OC4CCOCC4)c(ncn3)Nc5c(ccc6c5OCO6)Cl
Inchi Key=OUKYUETWWIPKQR-UHFFFAOYSA-N
nan nan Achiral Molecule AZ-10353926
AZD0530 DIFUMARATE
SARACATINIB DIFUMARATE
AZD0530
SARACATINIB
AZD-0530
Pacritinib
3 Cell Therapeutics ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
6T3 5lbz nan 0 472.2 5 68.7 7 1 4 nan JAK2 Smiles=c1cc2cc(c1)-c3ccnc(n3)Nc4ccc(c(c4)COC/C=C/COC2)OCCN5CCCC5
Inchi Key=HWXVIOGONBBTBY-ONEGZZNKSA-N
nan nan Achiral Molecule SB-1518
ONX-0803
SB1518
PACRITINIB
Tivozanib
3 Aveo Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
AV9 4ase 2 1 454.1 5.6 107.7 7 2 6 nan FLT1
KDR
FLT4
Smiles=Cc1cc(no1)NC(=O)Nc2ccc(cc2Cl)Oc3ccnc4c3cc(c(c4)OC)OC
Inchi Key=SPMVMDHWKHCIDT-UHFFFAOYSA-N
nan nan Achiral Molecule TIVOZANIB
KRN-951
KIL8951
Kil-8951
TIVOZANIB HYDROCHLORIDE
ASP-4130
AV-951
Volasertib
3 Boehringer Ingelheim ChemSpider
ChEMBL
DrugBank
RCSB
PDBe
Guide to Pharmacology
FDA SRS
BindingDB
IBI 3fc2 1 1 618.4 4.3 106.2 9 2 10 nan PLK1 Smiles=CC[C@H]1N(c2nc(ncc2N(C1=O)C)Nc3c(cc(cc3)C(=O)N[C@H]4CC[C@@H](CC4)N5CCN(CC5)CC6CC6)OC)C(C)C
Inchi Key=SXNJFOWDRLKDSF-STROYTFGSA-N
nan nan Single Stereoisomer VOLASERTIB
BI-6727
BI 6727
VOLASERTIB TRIHYDROCHLORIDE
BI 6727 CL3
Lorlatinib
3 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
53P NaN 1 0 406.2 2.8 110.1 7 1 0 nan ALK
ROS1
Smiles=C[C@@H]1c2cc(ccc2C(=O)N(Cc3c(c(n(n3)C)C#N)-c4cc(c(nc4)N)O1)C)F
Inchi Key=IIXWYSCJSQVBQM-LLVKDONJSA-N
nan nan Single Stereoisomer LORLATINIB
PF-06463922
Rociletinib
3 Clovis Oncology ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
8JC 5xdk 5xdl nan 1 555.2 4.8 111.7 8 3 8 nan EGFR Smiles=CC(=O)N1CCN(CC1)c2ccc(c(c2)OC)Nc3ncc(c(n3)Nc4cccc(c4)NC(=O)C=C)C(F)(F)F
Inchi Key=HUFOZJXAKZVRNJ-UHFFFAOYSA-N
nan nan Achiral Molecule CO-1686
CNX-419
ROCILETINIB
AVL-301
Upadacitinib
3 Abbvie ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 380.2 2.9 78.3 4 2 3 nan JAK1 Smiles=CC[C@@H]1CN(C[C@@H]1c2cnc3n2c4cc[nH]c4nc3)C(=O)NCC(F)(F)F
Inchi Key=WYQFJHHDOKWSHR-MNOVXSKESA-N
nan nan Single Stereoisomer ABT-494
UPADACITINIB TARTRATE
UPADACITINIB
Pyrotinib
3 Hengrui Therapeutics ChemSpider
ChEMBL
PubChem
ZINC
FDA SRS
NaN NaN nan 2 582.2 6.5 112.4 8 2 10 nan EGFR
ERBB2
Smiles=CCOc1cc2c(cc1NC(=O)/C=C/[C@H]3CCCN3C)c(c(cn2)C#N)Nc4ccc(c(c4)Cl)OCc5ccccn5
Inchi Key=SADXACCFNXBCFY-IYNHSRRRSA-N
nan nan Single Stereoisomer
Vatalanib
3 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN nan 1 346.1 5 50.7 4 1 4 Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC). FLT1
KDR
FLT4
Smiles=c1ccc2c(c1)c(nnc2Nc3ccc(cc3)Cl)Cc4ccncc4
Inchi Key=YCOYDOIWSSHVCK-UHFFFAOYSA-N
nan nan Achiral Molecule VATALANIB
BAY-86-5127
PTK-787
ZK-222584
NVP-PTK787
PTK787
CGP-79787
CGP-79787D
K-222584
Quizartinib
3 Ambit Biosciences ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
P30 4rt7 4xuf 2 2 560.2 5.9 106.2 9 2 7 nan FLT3
CSF1R
KIT
Smiles=CC(C)(C)c1cc(no1)NC(=O)Nc2ccc(cc2)c3cn4c5ccc(cc5sc4n3)OCCN6CCOCC6
Inchi Key=CVWXJKQAOSCOAB-UHFFFAOYSA-N
nan nan Achiral Molecule AC010220
AC220
QUIZARTINIB DIHYDROCHLORIDE
ASP-2689
AC010220.2HCL
QUIZARTINIB
AC-220
Losmapimod
3 GlaxoSmithKline ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN nan 0 383.2 3.9 71.1 3 2 5 nan MAPK14
MAPK11
MAPK13
MAPK12
Smiles=Cc1c(cc(cc1F)C(=O)NC2CC2)c3ccc(cn3)C(=O)NCC(C)(C)C
Inchi Key=KKYABQBFGDZVNQ-UHFFFAOYSA-N
nan nan Achiral Molecule LOSMAPIMOD
GW856553X
GSK-AHAB
GW-856553
Tivantinib
3 Daiichi Sankyo ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
TIV 5cb4 nan 0 369.1 3.6 66.9 3 2 2 nan MET Smiles=c1ccc2c(c1)c(c[nH]2)[C@H]3[C@@H](C(=O)NC3=O)c4cn5c6c4cccc6CCC5
Inchi Key=UCEQXRCJXIVODC-PMACEKPBSA-N
nan nan Single Stereoisomer TIVANTINIB
ARQ-197
ARQ 197
Linsitinib
3 Osi Pharmaceuticals ChemSpider
ChEMBL
PubChem
ZINC
BindingDB
NaN NaN nan 0 421.2 4.8 89.3 6 2 3 nan IGF1R Smiles=C[C@]1(C[C@@H](C1)c2n3c(c(ncc3)N)c(n2)c4cc5nc(ccc5cc4)c6ccccc6)O
Inchi Key=PKCDDUHJAFVJJB-UHFFFAOYSA-N
nan nan Single Stereoisomer
Itacitinib
3 Incyte Corporation ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 1 553.2 3.6 119.6 8 1 5 nan JAK1 Smiles=c1cnc-2[nH]cnc(c12)c3cnn(c3)C4(CN(C4)C5CCN(CC5)C(=O)c6ccnc(c6F)C(F)(F)F)CC#N
Inchi Key=KTBSXLIQKWEBRB-UHFFFAOYSA-N
nan nan Achiral Molecule ITACITINIB ADIPATE
INCB-039110
INCB039110
ITACITINIB
INCB-39110
INCB039110 adipate
Orantinib
3 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
SU6 4jlc 1 0 310.1 3.1 82.2 2 3 4 nan KDR
PDGFRB
FGFR1
Smiles=Cc1c(c([nH]c1/C=C\2/c3ccccc3NC2=O)C)CCC(=O)O
Inchi Key=NHFDRBXTEDBWCZ-ZROIWOOFSA-N
nan nan Achiral Molecule Orantinib
SU-6668
TSU-68
Canertinib
3 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN nan 0 485.2 4.4 88.6 7 2 9 Investigated for use/treatment in breast cancer and lung cancer. EGFR Smiles=C=CC(=O)Nc1cc2c(cc1OCCCN3CCOCC3)ncnc2Nc4ccc(c(c4)Cl)F
Inchi Key=OMZCMEYTWSXEPZ-UHFFFAOYSA-N
nan nan Achiral Molecule CANERTINIB
CANERTINIB DIHYDROCHLORIDE
SN-26606
CI-1033
PD-0183805
PD-183805
Encorafenib
3 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 1 539.2 3.9 140.1 9 3 9 nan BRAF Smiles=C[C@@H](CNc1nccc(n1)c2cn(nc2c3cc(cc(c3F)NS(=O)(=O)C)Cl)C(C)C)NC(=O)OC
Inchi Key=CMJCXYNUCSMDBY-ZDUSSCGKSA-N
nan nan Single Stereoisomer ENCORAFENIB
NVP-LGX818
LGX-818
NVP-LGX818-NXA
Alisertib
3 Millennium Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
A5B 5ia0 1 2 518.1 5.7 105.9 7 2 6 For the treatment of various forms of cancer. AURKA Smiles=COc1cccc(c1C2=NCc3cnc(nc3-c4c2cc(cc4)Cl)Nc5ccc(c(c5)OC)C(=O)O)F
Inchi Key=ZLHFILGSQDJULK-UHFFFAOYSA-N
nan nan Achiral Molecule MLN8237-004
MLN8237
ALISERTIB SODIUM
ALISERTIB
MLN-8237
Fruquintinib
3 Hutchison MediPharma ChemSpider
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 393.1 3.9 95.7 7 1 5 nan FLT1
KDR
FLT4
Smiles=Cc1c(c2ccc(cc2o1)Oc3c4cc(c(cc4ncn3)OC)OC)C(=O)NC
Inchi Key=BALLNEJQLSTPIO-UHFFFAOYSA-N
nan nan Single Stereoisomer
HMP-013
Fedratinib
3 Sanofi ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
2TA 4ogj 4ps5 nan 1 524.3 4.8 108.5 8 3 10 nan JAK2
FLT3
BRD4
Smiles=Cc1cnc(nc1Nc2cccc(c2)S(=O)(=O)NC(C)(C)C)Nc3ccc(cc3)OCCN4CCCC4
Inchi Key=JOOXLOJCABQBSG-UHFFFAOYSA-N
nan nan Achiral Molecule TG101348
TG-101348
SAR302503
FEDRATINIB
SAR-302503
Fostamatinib
3 Rigel; Dsm Pharma Chemicals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
2RC 4o75 nan 2 580.1 3.1 186.7 12 4 10 nan SYK Smiles=CC1(C(=O)N(c2c(ccc(n2)Nc3c(cnc(n3)Nc4cc(c(c(c4)OC)OC)OC)F)O1)COP(=O)(O)O)C
Inchi Key=GKDRMWXFWHEQQT-UHFFFAOYSA-N
nan nan Achiral Molecule R935788 FREE ACID
FOSTAMATINIB
FOSTAMATINIB DISODIUM
R788 FREE ACID
R788 SODIUM
R935788 SODIUM
R-935788
R-788
Binimetinib
3 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 440 3 88.4 6 3 6 nan MAP2K1 Smiles=Cn1cnc2c1cc(c(c2F)Nc3ccc(cc3F)Br)C(=O)NOCCO
Inchi Key=ACWZRVQXLIRSDF-UHFFFAOYSA-N
nan nan Achiral Molecule ARRY-438162
NVP-MEK162
ARRY-162
MEK-162
MEK162
BINIMETINIB
Dacomitinib
3 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
1C9 4i23 4i24 1 1 469.2 5.2 79.4 6 2 7 nan EGFR Smiles=COc1cc2c(cc1NC(=O)/C=C/CN3CCCCC3)c(ncn2)Nc4ccc(c(c4)Cl)F
Inchi Key=LVXJQMNHJWSHET-AATRIKPKSA-N
nan nan Achiral Molecule PF-00299804
DACOMITINIB
PF-00299804-03
Gilteritinib
3 Astellas Pharma ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN nan 1 552.4 2.7 121.1 10 3 9 nan FLT3
AXL
ALK
Smiles=CCc1c(nc(c(n1)C(=O)N)Nc2ccc(c(c2)OC)N3CCC(CC3)N4CCN(CC4)C)NC5CCOCC5
Inchi Key=GYQYAJJFPNQOOW-UHFFFAOYSA-N
nan nan Achiral Molecule ASP2215
GILTERITINIB FUMARATE
ASP-2215
GILTERITINIB
ASP2215 HEMIFUMARATE
Famitinib
3 Jiangsu Hengrui Medicine ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN nan 0 410.2 3.3 68.4 3 2 6 nan KIT
KDR
FLT4
PDGFRA
PDGFRB
FLT1
FLT3
Smiles=CCN(CC)CCN1CCc2c(c(c([nH]2)/C=C\3/c4cc(ccc4NC3=O)F)C)C1=O
Inchi Key=GKEYKDOLBLYGRB-LGMDPLHJSA-N
nan nan Single Stereoisomer SHR-1020
Barasertib
3 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN nan 1 587.2 3.6 174.8 9 5 15 nan AURKB Smiles=CCN(CCCOc1ccc2c(c1)ncnc2Nc3cc(n[nH]3)CC(=O)Nc4cccc(c4)F)CCOP(=O)(O)O
Inchi Key=GBJVVSCPOBPEIT-UHFFFAOYSA-N
nan nan Achiral Molecule Barasertib
AZD-1152
Simotinib
3 Advenchen Laboratories ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 1 500.2 4.4 78 8 1 7 nan EGFR Smiles=COc1cc2c(cc1OCCN3CC4(CC4)C5(C3)OCCO5)c(ncn2)Nc6ccc(c(c6)Cl)F
Inchi Key=OXWUWXCJDBRCCG-UHFFFAOYSA-N
nan nan Achiral Molecule SIM-6802
Cediranib
3 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN nan 1 450.2 5.2 72.5 6 1 8 For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors. KDR Smiles=Cc1cc2c([nH]1)ccc(c2F)Oc3c4cc(c(cc4ncn3)OCCCN5CCCC5)OC
Inchi Key=XXJWYDDUDKYVKI-UHFFFAOYSA-N
nan nan Achiral Molecule Recentin
AZD-2171
AZD2171 MALEATE
AZD2171
RECENTIN
CEDIRANIB MALEATE
CEDIRANIB
ZD-2171
Ensartinib
3 Xcovery ChemSpider
PubChem
ZINC
FDA SRS
NaN NaN nan 1 560.2 4.7 122.5 7 3 6 nan ALK Smiles=C[C@@H]1CN(C[C@@H](N1)C)C(=O)c2ccc(cc2)NC(=O)c3cc(c(nn3)N)O[C@H](C)c4c(ccc(c4Cl)F)Cl
Inchi Key=GLYMPHUVMRFTFV-QLFBSQMISA-N
nan nan nan
X-396
ENSARTINIB
Flumatinib
3 Jiangsu Hengrui Medicine ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS
NaN NaN nan 2 562.2 5 99.2 8 2 7 nan BCR
ABL1
PDGFRB
KIT
Smiles=Cc1c(cc(cn1)NC(=O)c2ccc(c(c2)C(F)(F)F)CN3CCN(CC3)C)Nc4nccc(n4)c5cccnc5
Inchi Key=BJCJYEYYYGBROF-UHFFFAOYSA-N
nan nan Achiral Molecule Flumatinib
HHGV-678
Buparlisib
3 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
SD5 3sd5 5m7e 1 0 410.2 1.8 89.6 8 1 3 nan PIK3CA Smiles=c1c(c(cnc1N)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F
Inchi Key=CWHUFRVAEUJCEF-UHFFFAOYSA-N
nan nan Achiral Molecule BKM120-NX
BKM-120
BUPARLISIB
BKM120-AAA
NVP-BKM120
BUPARLISIB HYDROCHLORIDE
Filgotinib
3 Galapagos ChemSpider
ChEMBL
PubChem
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
2HB 4p7e 5ut5 1 0 425.2 2 96.7 7 1 5 nan JAK1 Smiles=c1cc(n2c(c1)nc(n2)NC(=O)C3CC3)c4ccc(cc4)CN5CCS(=O)(=O)CC5
Inchi Key=RIJLVEAXPNLDTC-UHFFFAOYSA-N
nan nan Achiral Molecule GLPG-0634
G146034_101
GLPG0634
G146034
FILGOTINIB
FILGOTINIB HYDROCHLORIDE
Duvelisib
3 Infinity Pharmacueticals ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 416.1 4.5 88.5 6 2 4 nan PIK3CD
PIK3CG
Smiles=C[C@@H](c1cc2cccc(c2c(=O)n1c3ccccc3)Cl)Nc4c5c([nH]cn5)ncn4
Inchi Key=SJVQHLPISAIATJ-ZDUSSCGKSA-N
nan nan Single Stereoisomer INK-1197
DUVELISIB
IPI-145
INK-1147
Dovitinib
3 Novartis ChemSpider
ChEMBL
DrugBank
RCSB
PDBe
ZINC
FDA SRS
BindingDB
38O 4tyi 5a46 5am6 5am7 5owq 1 0 392.2 2.5 94 5 3 2 nan FGFR3
VEGFA
FGFR1
PDGFRA
KIT
CSF1R
Smiles=CN1CCN(CC1)c2ccc3c(c2)[nH]c(n3)c4c(c5c(cccc5F)[nH]c4=O)N
Inchi Key=PIQCTGMSNWUMAF-UHFFFAOYSA-N
nan nan Achiral Molecule GFKI-258
CHIR-258
DOVITINIB LACTATE
TKI-258
DOVITINIB
NVP-TKI258
Dinaciclib
3 Schering-Plough ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 396.2 2.3 92.6 7 2 7 nan CDK4
CDK6
BRDT
Smiles=CCc1cnn2c1nc(cc2NCc3ccc[n+](c3)[O-])N4CCCC[C@H]4CCO
Inchi Key=PIMQWRZWLQKKBJ-SFHVURJKSA-N
nan nan Single Stereoisomer SCH 727965
MK-7965
SCH-727965
DINACICLIB
Alpelisib
3 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
1LT 4jps nan 0 441.1 3.8 101.2 5 2 4 nan PIK3CA Smiles=Cc1c(sc(n1)NC(=O)N2CCC[C@H]2C(=O)N)c3ccnc(c3)C(C)(C)C(F)(F)F
Inchi Key=STUWGJZDJHPWGZ-LBPRGKRZSA-N
nan nan Single Stereoisomer NVP-BYL719
BYL-719
Alpelisib
Brivanib
3 Bristol Myers Squibb ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN nan 0 370.1 3.5 84.7 6 2 5 nan KDR Smiles=Cc1cc2c([nH]1)ccc(c2F)Oc3c4c(c(cn4ncn3)OC[C@@H](C)O)C
Inchi Key=WCWUXEGQKLTGDX-LLVKDONJSA-N
nan nan Single Stereoisomer BRIVANIB
BMS-540215
Peficitinib
3 Astellas Pharma ChemSpider
ZINC
NaN NaN nan 0 326.2 2 104 4 4 3 nan JAK1
JAK2
JAK3
TYK2
Smiles=c1c[nH]c2c1c(c(cn2)C(=O)N)N[C@@H]3[C@@H]4C[C@@H]5C[C@H]3C[C@@](C5)(C4)O
Inchi Key=DREIJXJRTLTGJC-ZKVNVPQCSA-N
nan nan Racemic Mixture
ASP015K
ASP015K hydrobromide
Rigosertib
3 Onconova Therapeutics ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
6FS 5j18 5j2r 5ov7 nan 0 451.1 2.8 120.4 8 2 11 nan PIK3CA
PLK1
Smiles=COc1ccc(cc1NCC(=O)O)CS(=O)(=O)/C=C/c2c(cc(cc2OC)OC)OC
Inchi Key=OWBFCJROIKNMGD-BQYQJAHWSA-N
nan nan Achiral Molecule RIGOSERTIB
ON-01910
ON-01910.Na
RIGOSERTIB SODIUM
ON 01910.NA
ON 01910
Crenolanib
3 Arog Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
6T2 5lby 6bqp nan 0 443.2 3.9 78.4 7 1 5 nan FLT3
PDGFRA
PDGFRB
Smiles=CC1(COC1)COc2ccc3c(c2)ncn3c4ccc5cccc(c5n4)N6CCC(CC6)N
Inchi Key=DYNHJHQFHQTFTP-UHFFFAOYSA-N
nan nan Achiral Molecule CP-868596
CRENOLANIB
CRENOLANIB BESYLATE
ARO-002
CP-868
ARO-002-26
596-26
Trametinib
4 GlaxoSmithKline ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN 3 1 615.1 3.9 107.1 8 2 5

Trametinib is indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.

BRAF
MAP2K1
MAP2K2
Smiles=Cc1c2c(c(n(c1=O)C)Nc3ccc(cc3F)I)c(=O)n(c(=O)n2c4cccc(c4)NC(=O)C)C5CC5
Inchi Key=LIRYPHYGHXZJBZ-UHFFFAOYSA-N
2013 US-7378423-B2 Achiral Molecule TRAMETINIB
GSK1120212B
GSK1120212
TRAMETINIB DIMETHYL SULFOXIDE
Lenvatinib
4 Eisai ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
LEV 3wzd 1.5 0 426.1 4.1 115.6 5 3 6

Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.

FLT1
KDR
FLT4
FGFR1
FGFR2
FGFR3
FGFR4
KIT
Smiles=COc1cc2c(cc1C(=O)N)c(ccn2)Oc3ccc(c(c3)Cl)NC(=O)NC4CC4
Inchi Key=WOSKHXYHFSIKNG-UHFFFAOYSA-N
2015 US-7253286-B2 Achiral Molecule LENVATINIB
ER-203492-00
E7080
LENVATINIB MESYLATE
Imatinib
4 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
STI 1iep 1opj 1t46 1xbb 2hyy 2oiq 2pl0 3fw1 3gvu 3hec 3k5v 3ms9 3mss 3oez 3pyy 4bkj 4csv 4r7i 5mqt 2 0 493.3 4.6 86.3 7 2 7

For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).

KIT
RET
NTRK1
CSF1R
PDGFRA
DDR1
ABL1
PDGFRB
Smiles=Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)NC(=O)c4ccc(cc4)CN5CCN(CC5)C
Inchi Key=KTUFNOKKBVMGRW-UHFFFAOYSA-N
2001 US-6894051-B1 Achiral Molecule STI-571
STI 571
Gleevec
IMATINIB
Imatinib mesylate
Vandetanib
4 Ipr Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
ZD6 2ivu 1.5 1 474.1 5 59.5 6 1 6

Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.

VEGFA
EGFR
PTK6
TEK
RET
Smiles=CN1CCC(CC1)COc2cc3c(cc2OC)c(ncn3)Nc4ccc(cc4F)Br
Inchi Key=UHTHHESEBZOYNR-UHFFFAOYSA-N
2011 US-RE42353-E1 Achiral Molecule ZD-64
ZACTIMA
CAPRELSA
ZD-6474
VANDETANIB
ZD6474
GNF-Pf-2188
Tofacitinib
4 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
MI1 3eyg 3fup 3lxk 3lxn 4oti 1 0 312.2 1.5 88.9 5 1 3

For the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy. It may also be used as an adjunct to methotrexate therapy, or other non-biologic disease-modifying antirheumatic drugs (DMARDS), when methotrexate alone is not sufficient. Tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections, and as a treatment for psoriasis, ulcerative colitis, and ankylosing spondylitis. It is not to be initiated in patients with a history of chronic or recurrent infections, or in the presence of active infection, even if localized, due to reports of serious and sometimes fatal infections (commonly pneumonia, herpes zoster and urinary tract infections). Use of tofacitinib is also discouraged in those who have been, or are likely to be, exposed to TB. An increased likelihood of exposure may be encountered by traveling to certain areas. In addition, tofacitinib is not to be used in patients with severe hepatic impairment, or low hemoglobin (less than 9g/dL). Cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation, and in the elderly who are more susceptible to infection.

JAK1
JAK2
JAK3
TYK2
Smiles=C[C@@H]1CCN(C[C@@H]1N(C)c2c3cc[nH]c3ncn2)C(=O)CC#N
Inchi Key=UJLAWZDWDVHWOW-YPMHNXCESA-N
2012 US-6956041-B2 Single Stereoisomer TOFACITINIB
CP-690550-10
TASOCITINIB
TASOCITINIB CITRATE
550
CP-690
CP-690550
XELJANZ
TOFACITINIB CITRATE
Ceritinib
4 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
4MK 4mkc 1 2 557.2 6.4 105.2 8 3 9

Ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

ALK Smiles=Cc1cc(c(cc1C2CCNCC2)OC(C)C)Nc3ncc(c(n3)Nc4ccccc4S(=O)(=O)C(C)C)Cl
Inchi Key=VERWOWGGCGHDQE-UHFFFAOYSA-N
2014 US-7153964-B2 Achiral Molecule CERITINIB
NVP-LDK378-NX
Lapatinib
4 GlaxoSmithKline ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
FMM 1xkk 3bbt 1.5 2 580.1 6.1 106.4 8 2 11

Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma.

EGFR
ERBB2
Smiles=CS(=O)(=O)CCNCc1ccc(o1)c2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5cccc(c5)F
Inchi Key=BCFGMOOMADDAQU-UHFFFAOYSA-N
2007 US-6391874-B1 Achiral Molecule GW-572016
GW-2016
Lapatinib
TYKERB
Lapatinib ditosylate monohydrate
LAPATINIB DITOSYLATE
LAPATINIB
GW572016F
Sunitinib
4 Cp Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
B49 2y7j 3g0e 3g0f 3miy 3ti1 4agd 4ks8 4qmz 1 0 398.2 3.3 77.2 3 3 7

For the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.

PDGFRB
FLT1
KIT
KDR
FLT4
FLT3
CSF1R
PDGFRA
Smiles=CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)F)C
Inchi Key=WINHZLLDWRZWRT-ATVHPVEESA-N
2006 US-6573293-B2 Achiral Molecule SU-11248
SUNITINIB
Sutent
SUNITINIB MALATE
Cobimetinib
4 Hoffmann-La Roche ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
EUI 4an2 4lmn 3 1 531.1 3.8 64.6 4 3 4

For the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Cobimetinib is used in combination with vemurafenib, a BRAF inhibitor.

MAP2K1 Smiles=c1c(cc(c(c1)Nc2c(c(ccc2C(=O)N3C[C@@](C3)(O)[C@H]4NCCCC4)F)F)F)I
Inchi Key=BSMCAPRUBJMWDF-KRWDZBQOSA-N
2015 US-7803839-B2 Single Stereoisomer COBIMETINIB FUMARATE
GDC-0973
XL-518
COBIMETINIB
RG-7421
RG 7420
Dasatinib
4 Bristol Myers Squibb ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
1N1 2gqg 2y6o 2zva 3g5d 3k54 3lfa 3oct 3oht 3qlg 3sxr 4qms 4xey 4xli 5bvw 5h2u 5i9y 5owr 5vcv 1 0 487.2 3.3 106.5 9 3 7

For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.

ABL1
SRC
EPHA2
LCK
YES1
KIT
PDGFRB
ABL2
FYN
Smiles=Cc1cccc(c1NC(=O)c2cnc(s2)Nc3cc(nc(n3)C)N4CCN(CC4)CCO)Cl
Inchi Key=ZBNZXTGUTAYRHI-UHFFFAOYSA-N
2006 US-6596746-B1 Achiral Molecule SPRYCEL
BMS-354825-03
DASATINIB
BMS-354825
Ruxolitinib
4 Incyte Corp ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
RXT 4u5j 1 0 306.2 3.5 83.2 5 1 4

Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis. [Lexicomp] Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).

JAK1
JAK2
Smiles=c1c[nH]c2c1c(ncn2)c3cnn(c3)[C@H](CC#N)C4CCCC4
Inchi Key=HFNKQEVNSGCOJV-OAHLLOKOSA-N
2011 US-7598257-B2 Single Stereoisomer RUXOLITINIB
INCB018424 SALT
INCB-018424
RUXOLITINIB PHOSPHATE
Jakafi
Dabrafenib
4 GlaxoSmithKline ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
P06 4xv2 5csw 5hie 1.5 2 519.1 5.4 110.9 7 2 5

Dabrafenib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.

BRAF
RAF1
SIK1
NEK11
LIMK1
Smiles=CC(C)(C)c1nc(c(s1)c2ccnc(n2)N)c3cccc(c3F)NS(=O)(=O)c4c(cccc4F)F
Inchi Key=BFSMGDJOXZAERB-UHFFFAOYSA-N
2013 US-7994185-B2 Achiral Molecule DABRAFENIB MESYLATE
GSK2118436A
GSK2118436B
DABRAFENIB
METHANE SULFONATE SALT
Ribociclib
4 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
6ZZ 5l2t 1 0 434.3 2.8 91.2 8 2 5

Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably.

CDK4
CDK6
Smiles=CN(C)C(=O)c1cc2cnc(nc2n1C3CCCC3)Nc4ccc(cn4)N5CCNCC5
Inchi Key=RHXHGRAEPCAFML-UHFFFAOYSA-N
2017 nan Achiral Molecule LEE-011
RIBOCICLIB SUCCINATE
RIBOCICLIB
LEE011-BBA
Ribociclib
NVP-LEE011
Gefitinib
4 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
IRE 2ito 2ity 2itz 3ug2 4i22 4wkq 1.5 0 446.2 4.3 68.7 7 1 8

For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.

EGFR Smiles=COc1cc2c(cc1OCCCN3CCOCC3)c(ncn2)Nc4ccc(c(c4)Cl)F
Inchi Key=XGALLCVXEZPNRQ-UHFFFAOYSA-N
2003 US-5770599-A Achiral Molecule GEFITINIB
Iressa
ZD-1839
ZD1839
Nintedanib
4 Boehringer Ingelheim ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
XIN 3c7q 5maf 5te0 1 1 539.3 3.6 94.2 7 2 7 Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). FLT1
KDR
FLT4
FGFR1
FGFR2
FGFR3
FLT3
LCK
LYN
SRC
Smiles=CN1CCN(CC1)CC(=O)N(C)c2ccc(cc2)N/C(=C\3/c4ccc(cc4NC3=O)C(=O)OC)/c5ccccc5
Inchi Key=XZXHXSATPCNXJR-ZIADKAODSA-N
2014 US-6762180-B1 Achiral Molecule BIBF-1120
NINTEDANIB
BIBF 1120
NINTEDANIB ESYLATE
Erlotinib
4 Osi Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
AQ4 1m17 4hjo 1.5 0 393.2 3.4 74.7 7 1 10

For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

EGFR
NR1I2
Smiles=COCCOc1cc2c(cc1OCCOC)ncnc2Nc3cccc(c3)C#C
Inchi Key=AAKJLRGGTJKAMG-UHFFFAOYSA-N
2004 US-5747498-A Achiral Molecule CP-358774-01
RG-1415
ERLOTINIB HYDROCHLORIDE
CP-358774
OSI-774
CP-358,774-01
ERLOTINIB
Ro-508231
R-1415
TARCEVA
Sorafenib
4 Bayer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
BAX 1uwh 1uwj 3gcs 3heg 3rgf 3wze 4asd 5hi2 2 1 464.1 5.5 92.3 4 3 5 Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. BRAF
RAF1
FLT4
KDR
FLT3
PDGFRB
KIT
FGFR1
RET
FLT1
Smiles=CNC(=O)c1cc(ccn1)Oc2ccc(cc2)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl
Inchi Key=MLDQJTXFUGDVEO-UHFFFAOYSA-N
2005 US-7235576-B1 Achiral Molecule SORAFENIB TOSYLATE
SORAFENIB
BAY 54-9085
NEXAVAR
BAY 43-9006
Nexavar
[11C]-Sorafenib
BAY-43-9006
Vemurafenib
4 Hoffmann-La Roche ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
32 3og7 4rzv 5hes 1.5 1 489.1 5.5 91.9 4 2 7

Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E.

BRAF Smiles=CCCS(=O)(=O)Nc1ccc(c(c1F)C(=O)c2c[nH]c3c2cc(cn3)c4ccc(cc4)Cl)F
Inchi Key=GPXBXXGIAQBQNI-UHFFFAOYSA-N
2011 US-7504509-B2 Achiral Molecule ZELBORAF
VEMURAFENIB
RG 7204
PLX-4032
RO 5185426
Abemaciclib
4 Eli Lilly ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
6ZV 5l2s 1 1 506.3 4.9 75 8 1 7

On September 28, 2017, the Food and Drug Administration approved abemaciclib (VERZENIO, Eli Lilly and Company) in combination with fulvestrant for women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. In addition, abemaciclib was approved as monotherapy for women and men with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.

CDK4
CDK6
Smiles=CCN1CCN(CC1)Cc2ccc(nc2)Nc3ncc(c(n3)c4cc5c(c(c4)F)nc(n5C(C)C)C)F
Inchi Key=UZWDCWONPYILKI-UHFFFAOYSA-N
nan nan Achiral Molecule LY-2835219
LY2835219
ABEMACICLIB
Icotinib
4 Zhejiang Beta Pharma ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN nan 0 391.2 3.2 74.7 7 1 2

Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.

EGFR Smiles=C#Cc1cccc(c1)Nc2c3cc4c(cc3ncn2)OCCOCCOCCO4
Inchi Key=QQLKULDARVNMAL-UHFFFAOYSA-N
nan nan nan BPI-2009H
Brigatinib
4 Ariad Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
ZINC
FDA SRS
6GY 5j7h 1 2 583.3 5.1 85.9 9 2 8

The anaplastic lymphoma kinase positive, metastatic non-small cell lung cancer (ALK+ NSCLC), represents only 3-5% of the NSCLC cancer cases, but the ALK mutation, overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy target. The ALK-related cases of NSCLC are associated with the presence of the fusion gene EML4-ALK which fused the ALK protein with the echinoderm microtubule-associated protein like-4 whose original function is the correct formation of microtubules. The presence of the aberrant fusion protein results in abnormal signaling that provokes increased cell growth, proliferation and survival. Crizotinib is indicated for the treatment of such cases but the presence of ALK kinase domain mutations confer resistance to the treatment. Thus, brigatinib is indicated for the treatment of patients with ALK+ NSCLC with intolerance to Crizotinib.

ALK
EGFR
Smiles=CN1CCN(CC1)C2CCN(CC2)c3ccc(c(c3)OC)Nc4ncc(c(n4)Nc5ccccc5P(=O)(C)C)Cl
Inchi Key=AILRADAXUVEEIR-UHFFFAOYSA-N
nan nan Achiral Molecule AP26113
AP-26113
BRIGATINIB
Copanlisib
4 Bayer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
600 5g2n 1 1 480.2 0.7 139.8 11 2 7 Indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. PIK3CA
PIK3CB
Smiles=COc1c(ccc2c1N=C(N3C2=NCC3)NC(=O)c4cnc(nc4)N)OCCCN5CCOCC5
Inchi Key=PZBCKZWLPGJMAO-UHFFFAOYSA-N
nan nan Achiral Molecule COPANLISIB HYDROCHLORIDE
BAY 84-1236
COPANLISIB
BAY-80-6946
BAY 80-6946
Neratinib
4 Puma Biotechnology ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN nan 2 556.2 5.9 112.4 8 2 11

For use as an extended adjuvant treatment in adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy

ERBB2
EGFR
Smiles=CCOc1cc2c(cc1NC(=O)/C=C/CN(C)C)c(c(cn2)C#N)Nc3ccc(c(c3)Cl)OCc4ccccn4
Inchi Key=JWNPDZNEKVCWMY-VQHVLOKHSA-N
nan nan Achiral Molecule NERATINIB
WAY-179272
HKI-272
CDP-820
Cabozantinib
4 Exelixis ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN 2 2 501.2 5.5 98.8 6 2 8

For the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

MET
KDR
RET
Smiles=COc1cc2c(ccnc2cc1OC)Oc3ccc(cc3)NC(=O)C4(CC4)C(=O)Nc5ccc(cc5)F
Inchi Key=ONIQOQHATWINJY-UHFFFAOYSA-N
2012 US-7579473-B2 Achiral Molecule CABOZANTINIB
COMETRIQ
XL-184
BMS-907351
CABOZANTINIB S-MALATE
XL184
Idelalisib
4 Gilead Sciences ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
40L 4xe0 1 0 415.2 3.8 101.4 7 2 5

Idelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.

PIK3CD Smiles=CC[C@@H](c1nc2cccc(c2c(=O)n1c3ccccc3)F)Nc4c5c([nH]cn5)ncn4
Inchi Key=IFSDAJWBUCMOAH-HNNXBMFYSA-N
2014 US-6800620-B2 Single Stereoisomer IDELALISIB
GS-1101
CAL-101
GS-11CAL-101
Nilotinib
4 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NIL 3cs9 3gp0 5mo4 2 2 529.2 6.4 97.6 7 2 6 For the potential treatment of various leukemias, including chronic myeloid leukemia (CML). ABL1
KIT
Smiles=Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)C(=O)Nc4cc(cc(c4)n5cc(nc5)C)C(F)(F)F
Inchi Key=HHZIURLSWUIHRB-UHFFFAOYSA-N
2007 US-7169791-B2 Achiral Molecule NILOTINIB
TASIGNA
NILOTINIB HYDROCHLORIDE MONOHYDRATE
AMN 107
Baricitinib
4 Eli Lilly ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
3JW 4w9x 1 0 371.1 1.1 120.6 7 1 5

Indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs as monotherapy or in combination with methotrexate.

JAK1
JAK2
Smiles=CCS(=O)(=O)N1CC(C1)(CC#N)n2cc(cn2)c3c4cc[nH]c4ncn3
Inchi Key=XUZMWHLSFXCVMG-UHFFFAOYSA-N
nan nan Achiral Molecule LY3009104
INCB028050
INCB-28050
BARICITINIB
LY-3009104
Axitinib
4 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
AXI 4ag8 4agc 4twp 4wa9 2 0 386.1 4.6 70.7 4 2 5 Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer. FLT1
KDR
FLT4
Smiles=CNC(=O)c1ccccc1Sc2ccc3c(c2)[nH]nc3/C=C/c4ccccn4
Inchi Key=RITAVMQDGBJQJZ-FMIVXFBMSA-N
2012 US-6534524-B1 Achiral Molecule AG-013736
AXITINIB
AG-13736
Inlyta
Ibrutinib
4 Pharmacyclics ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
100000000 4ifg 4rz7 5p9i 5yu9 1.5 0 440.2 4.2 99.2 7 1 5

Ibrutinib was approved by the FDA for the treatment of mantle cell lymphoma, and later in February 2014 for the treatment of chronic lymphocytic leukemia

BTK Smiles=C=CC(=O)N1CCC[C@H](C1)n2c3c(c(n2)c4ccc(cc4)Oc5ccccc5)c(ncn3)N
Inchi Key=XYFPWWZEPKGCCK-GOSISDBHSA-N
2013 US-7514444-B2 Single Stereoisomer PCI-32765
PCI-32765-00
CRA-032765
IBRUTINIB
Apatinib
4 Bukwang Pharmaceutical ChemSpider
PubChem
NaN NaN nan 0 493.2 3.1 152.5 7 2 5

Apatinib mesylate is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. The free-base form is also known as Rivoceranib. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.

KDR Smiles=N#CC1(CCCC1)c1ccc(cc1)NC(=O)c1cccnc1Nc1cnccc1C Cc1ccncc1Nc2c(cccn2)C(=O)Nc3ccc(cc3)C4(CCCC4)C#N
Inchi Key=MGZNERAVOCFMCU-UHFFFAOYSA-N
nan nan Achiral Molecule
APATINIB
AITAN
APATINIB TABLETS
YN968D1
Palbociclib
4 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
LQQ 2euf 5l2i 1 0 447.2 3 105 9 2 5

Palbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

CDK4
CDK6
Smiles=Cc1c2cnc(nc2n(c(=O)c1C(=O)C)C3CCCC3)Nc4ccc(cn4)N5CCNCC5
Inchi Key=AHJRHEGDXFFMBM-UHFFFAOYSA-N
2015 US-6936612-B2 Achiral Molecule PD-0332991
PD 0332991-0054
PALBOCICLIB
PALBOCICLIB ISETHIONATE
PF-00080665-73
Alectinib
4 Hoffmann-La Roche ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
EMH 3aox 1 0 482.3 4.8 72.4 5 1 3

Alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

ALK Smiles=CCc1cc2c(cc1N3CCC(CC3)N4CCOCC4)C(c5c(c6ccc(cc6[nH]5)C#N)C2=O)(C)C
Inchi Key=KDGFLJKFZUIJMX-UHFFFAOYSA-N
2015 US-9126931-B2 Achiral Molecule ALECTINIB
CH5424802
AF802
ALECTINIB HYDROCHLORIDE
Afatinib
4 Boehringer Ingelheim ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
0WM 4g5j 1 0 485.2 4.4 88.6 7 2 8

Afatinib is a kinase inhibitor indicated for the first-line treatment of patient with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.

EGFR
ERBB2
ERBB4
Smiles=CN(C)C/C=C/C(=O)Nc1cc2c(cc1O[C@H]3CCOC3)ncnc2Nc4ccc(c(c4)Cl)F
Inchi Key=ULXXDDBFHOBEHA-CWDCEQMOSA-N
2013 US-6251912-B1 Single Stereoisomer BIBW-2992
AFATINIB
AFATINIB DIMALEATE
BIBW2992 MA2
BIBW2992
Osimertinib
4 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
YY3 4zau 1 0 499.3 4.5 87.6 8 2 10

Osimertinib is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA- approved test, who have progressed on or after EGFR-TKI therapy.

EGFR Smiles=Cn1cc(c2c1cccc2)c3ccnc(n3)Nc4cc(c(cc4OC)N(C)CCN(C)C)NC(=O)C=C
Inchi Key=DUYJMQONPNNFPI-UHFFFAOYSA-N
2015 US-8946235-B2 Achiral Molecule AZD9291
AZD9291 mesylate
OSIMERTINIB MESYLATE
OSIMERTINIB
AZD-9291
Ponatinib
4 Ariad Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
0LI 3ik3 3oxz 3zos 4c8b 4qrc 4tyj 4u0i 4uxq 4v01 4v04 2 1 532.2 4.5 65.8 6 1 4

Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.

ABL1
BCR
KIT
RET
TEK
FLT3
FGFR1
FGFR2
FGFR3
FGFR4
LCK
SRC
LYN
KDR
PDGFRA
Smiles=Cc1ccc(cc1C#Cc2cnc3n2nccc3)C(=O)Nc4ccc(c(c4)C(F)(F)F)CN5CCN(CC5)C
Inchi Key=PHXJVRSECIGDHY-UHFFFAOYSA-N
2012 US-8114874-B2 Achiral Molecule PONATINIB
AP24534
PONATINIB HYDROCHLORIDE
ICLUSIG
AP24534 HCL
Bosutinib
4 Wyeth ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
DB8 3soa 3ue4 4mxo 4mxx 4mxy 4mxz 4otw 4qmn 5ajq 5i9x 5vc3 5vcy 1 2 529.2 5.2 82.9 8 1 9

Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.

BCR
ABL1
LYN
HCK
SRC
CDK2
MAP2K1
MAP2K2
MAP3K2
CAMK2G
Smiles=CN1CCN(CC1)CCCOc2cc3c(cc2OC)c(c(cn3)C#N)Nc4cc(c(cc4Cl)Cl)OC
Inchi Key=UBPYILGKFZZVDX-UHFFFAOYSA-N
2010 US-6002008-A Achiral Molecule BOSUTINIB
BOSUTINIB MONOHYDRATE
SKI-606
BOSULIF
Crizotinib
4 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
VGH 2wgj 2xp2 2yfx 3zbf 4anq 4ans 4c9w 5aaa 5aab 5aac 1 1 449.1 5 78 6 2 5

Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.

ALK
MET
Smiles=C[C@H](c1c(ccc(c1Cl)F)Cl)Oc2cc(cnc2N)c3cnn(c3)C4CCNCC4
Inchi Key=KTEIFNKAUNYNJU-GFCCVEGCSA-N
2011 US-7230098-B2 Single Stereoisomer XALKORI
PF-2341066
CRIZOTINIB
Regorafenib
4 Bayer ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN 2 1 482.1 5.7 92.3 4 3 5

Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.

FLT1
KDR
FLT4
KIT
PDGFRA
PDGFRB
FGFR1
FGFR2
TEK
DDR2
NTRK1
EPHA2
RAF1
BRAF
MAPK11
FRK
ABL1
RET
Smiles=CNC(=O)c1cc(ccn1)Oc2ccc(c(c2)F)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl
Inchi Key=FNHKPVJBJVTLMP-UHFFFAOYSA-N
2012 US-7351834-B1 Achiral Molecule REGORAFENIB
STIVARGA
BAY 73-4506 MONOHYDRATE
BAY 73-4506
Pazopanib
4 GlaxoSmithKline ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN NaN 1 0 437.2 3.1 119 8 2 5 Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy) FLT1
KDR
FLT4
PDGFRA
PDGFRB
KIT
FGFR3
ITK
FGFR1
Smiles=Cc1ccc(cc1S(=O)(=O)N)Nc2nccc(n2)N(C)c3ccc4c(n(nc4c3)C)C
Inchi Key=CUIHSIWYWATEQL-UHFFFAOYSA-N
2009 US-7105530-B2 Achiral Molecule PAZOPANIB HYDROCHLORIDE
GW786034B
GW-786034
PAZOPANIB
VOTRIENT
Acalabrutinib
4 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
NaN NaN nan 0 465.2 3.3 118.5 7 2 4 Acalabrutinib is currently indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy BTK Smiles=CC#CC(=O)N1CCC[C@H]1c2nc(c3n2ccnc3N)c4ccc(cc4)C(=O)Nc5ccccn5
Inchi Key=WDENQIQQYWYTPO-IBGZPJMESA-N
nan nan Single Stereoisomer ACP-196
ACALABRUTINIB